Requisite Capital Management LLC Sells 9,626 Shares of Merck & Co., Inc. $MRK

Requisite Capital Management LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 83.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,924 shares of the company’s stock after selling 9,626 shares during the period. Requisite Capital Management LLC’s holdings in Merck & Co., Inc. were worth $204,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of MRK. United Financial Planning Group LLC acquired a new stake in shares of Merck & Co., Inc. in the third quarter worth $31,000. Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. during the 3rd quarter valued at $34,000. Dunhill Financial LLC boosted its holdings in Merck & Co., Inc. by 83.0% in the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after purchasing an additional 190 shares during the period. Silicon Valley Capital Partners boosted its holdings in Merck & Co., Inc. by 160.5% in the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after purchasing an additional 260 shares during the period. Finally, J.Safra Asset Management Corp grew its position in Merck & Co., Inc. by 53.6% in the 3rd quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock worth $38,000 after purchasing an additional 157 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $111.36 on Monday. The company has a 50-day moving average of $116.00 and a 200-day moving average of $109.36. The company has a market capitalization of $275.03 billion, a price-to-earnings ratio of 31.37, a PEG ratio of 2.51 and a beta of 0.18. Merck & Co., Inc. has a 52 week low of $74.37 and a 52 week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Barclays started coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. JPMorgan Chase & Co. boosted their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Guggenheim upped their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, Cantor Fitzgerald raised their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.